Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial

European Journal of Ophthalmology

Volumn 21, Issue 6, 2011, Pages 789-795

  Algvere, Peep V ^a   Epstein, David ^a   von Wendt, Gunvor ^a   Seregard, Stefan ^a   Kvanta, Anders ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

Central retinal vein occlusion; Clinical trial; Intravitreal bevacizumab; Macular edema; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CHLORHEXIDINE; DORZOLAMIDE PLUS TIMOLOL; FUSIDIC ACID;

ADULT; AGED; ARGON LASER; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE DURATION; DRUG DOSE REGIMEN; EPIRETINAL MEMBRANE; EYE DISCOMFORT; EYE INFECTION; EYE INFLAMMATION; EYE IRRITATION; HUMAN; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; INTRARETINAL VACUOLE; IRIS RUBEOSIS; LASER COAGULATION; MACULAR THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; PARS PLANA VITRECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA; RETINA FOVEA; RETINA FOVEAL THICKNESS; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETREATMENT; SUBRETINAL FLUID; THICKNESS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80054111998     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2011.6522     Document Type: Article

References (31)

1. Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: 371-422.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
3. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 412-4.
4. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularisation and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120: 1644-50.
5. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and Interleukon-6. Am J Ophthalmol 2005; 140: 256-61.
6. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009; 116: 2158-64.
7. Dvorak HF, Bown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
9. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retina vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 1113-23.
10. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007; 27: 1013-9.
11. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-9.
12. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion. Retina 2007; 27: 1004-12.
13. Ferrara DC, Koizumi H, Spaide RF, et al. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144: 864-71.
14. ®) for macular edema secondary to retinal vein occlusion: twelve-month results of a prospective clinical trial. Br J Ophthalmol 2009; 93: 452-6.
15. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retina venous occlusive disease. Retina 2007; 27: 426-31.
16. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischemic central vein occlusion. Acta Ophthalmol 2009; 87: 77-81.
17. ®). Acta Ophthalmol 2010; 88: 836-41.
18. Rouvas A, Petrou P, Vergados I, et al. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1609-16.
19. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298-306.
20. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115: e47-54.
21. Brown DM, Campochiaro PA, Singh RP, et al, CRUISE Investigators CRUISE. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-33.
22. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N. Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010; 20: 180-5.
23. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the Pan-American collaborative retina study group at 24 months. Retina 2010; 30: 1002-11.
24. Miki K, Miki A, Matsuoka M, Muramatsu D, Hacket SF, Campochiaro P. Effects of intravitreal ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 2009; 116: 1748-54.
25. Julien S, Heiduschka P, Hofmeister S. Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. Br J Ophthalmol 2008; 92: 1424-8.
26. Klettner AK, Kruse M-L, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1601-8.
27. Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 2008; 49: 3164-71.
28. Schlichtenbrede FC, Mittmann W, Rench F, vom Hagen F, Jonas JB, Euler T. Toxicity assessment of intravitreal triamcinolone and bevacizumab in a retinal explant mouse model using two-photon microscopy. Invest Ophthalmol Vis Sci 2009; 50: 5880-7.
29. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of Pan-American Collaborative Retina Study Group. Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-7.
30. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009; 93: 457-62.
31. Fung AE, Rosenfeld PJ, Reichel E, et al. The international intravitreal bevacizumab safety survey: using the internet to assess drug worldwide. Br J Ophthalmol 2006; 90: 1344-9.